Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 495 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Buprenorphine Clear all
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Health Intervention to Support Opioid Use Disorder Treatment

NCT03842384
View directory record Official record
Conditions
Opioid Use Disorder, Treatment Adherence
Interventions
iENDURE
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

Effects of Buprenorphine and Naloxone in Opiate Addicts - 4

NCT00000355
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Not applicable Interventional

More Individualized Care: Assessment and Recovery Through Engagement

NCT05122676
View directory record Official record
Conditions
Depression, Anxiety, Opioid-Related Disorders, Pain, Chronic
Interventions
More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 7, 2026, 10:25 AM EDT
Recruiting Phase 2 Interventional

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT05778591
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Buprenorphine 0.15 MG [Belbuca]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 7, 2026, 10:25 AM EDT
Not yet recruiting Phase 3 Interventional

Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine

NCT07361432
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT), Enhanced Treatment as Usual (ETAU)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
West Haven, Connecticut • Bedford, Massachusetts • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Not applicable Interventional Results available

Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department

NCT00913770
View directory record Official record
Conditions
Opiate Addiction
Interventions
Brief Negotiation Interview (BNI), Buprenorphine Initiation
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 7, 2026, 10:25 AM EDT
Active, not recruiting Early Phase 1 Interventional

Digital Support Intervention for Pregnant People with Opioid Use Disorders

NCT06652880
View directory record Official record
Conditions
Digital Intervention, Bibliotherapy
Interventions
Digital technology, Bibliotherapy
Device · Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

NCT04995029
View directory record Official record
Conditions
Moderate to Severe Opioid-use Disorder
Interventions
Transmucosal Buprenorphine, Extended-release Buprenorphine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
785 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
28
States / cities
Garden Grove, California • Panorama City, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 7, 2026, 10:25 AM EDT
Withdrawn Phase 4 Interventional

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine

NCT06784180
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine, Bupivacaine, Fentanyl, Hydromorphone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

Alternate-Day Buprenorphine. Phase V - 6

NCT00000224
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
30 Years to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

Single-dose, Study of RBP-6000 in Opioid Dependent Individuals

NCT02765867
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 7, 2026, 10:25 AM EDT
Recruiting Not applicable Interventional

Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment

NCT07024498
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
care coordination implementation strategies
Other
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older
Enrollment
3,492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
El Centro, California • Irvine, California • Placerville, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 7, 2026, 10:25 AM EDT
Withdrawn Phase 4 Interventional

Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population

NCT04464512
View directory record Official record
Conditions
Addiction Opiate, Chronic Pain, Fractures, Bone, Buprenorphine Dependence
Interventions
Sufentanil
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

NCT02672111
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 7 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects

NCT01675167
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

Buprenorphine Combination Tablet Feasibility - 1

NCT00000298
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2005 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 2Phase 3 Interventional

Directly Administered HIV Therapy in Methadone Clinics

NCT00279110
View directory record Official record
Conditions
HIV Infections, Heroin Dependence
Interventions
Directly administered antiretroviral therapy (DAART)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers

NCT02926482
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Prescriber Recruitment Bundle (PRB)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Tallahassee, Florida • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

Onsite Buprenorphine Treatment at Syringe Exchange Programs

NCT03150173
View directory record Official record
Conditions
Opiate Addiction
Interventions
Onsite treatment, Enhanced referral, Buprenorphine
Behavioral · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence

NCT00548275
View directory record Official record
Conditions
Opiate Dependence, HIV Infections
Interventions
Enhanced Sexual Risk Management, Standard Sexual Risk Management
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 7, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

NCT00000230
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 7, 2026, 10:25 AM EDT